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Community-acquired pneumonia (CAP) remains the leading cause of death by an infectious 
disease(1). Although the aetiological agent varies by geographical location and population studied in 
adults the most commonly isolated pathogens from adult CAP patients are bacteria. Despite the 
poor detection rate of CAP organisms by current microbiological techniques(2), Streptococcus 
pneumoniae continues to be the most frequently isolated pathogen(3) and is responsible for the 
huge burden associated with this disease. Other commonly isolated bacteria include Haemophilus 
influenzae, Mycoplasma pneumoniae, Chlamydophila pneumoniae and Legionella pneumophila. Less 
regularly Enterobacteriaceae, Pseudomonas aeruginosa, Klebsiella pneumoniae, Moraxella 
Catarrhalis, Chlamydia psittaci and Coxiella Burnetii are identified. With improved molecular 
diagnostics viruses are increasingly being recognised as important pathogens in CAP particularly as 
they predispose the host to secondary bacterial infection. Treatment of CAP therefore requires the 
use of antibiotics but as clinical or radiological features are not adequate to determine the 
aetiological agent, and due to the delay in microbiological diagnosis these have to be administered 
empirically. Although this is an extremely useful strategy at the early stage of treatment it is 
important to move to definitive less broad-spectrum treatment once a culprit pathogen has been 
identified to limit the emergence of antibiotic-resistant bacteria. Another important consideration in 
the treatment of CAP is the route of administration. Whilst intravenous formulations are useful for 
those who are clinically unstable or unable to take medication orally, by ensuring optimal 
bioavailability, this is associated with increased cost and infusion site adverse events. It is therefore 
important to ensure that when appropriate antibiotics are switched from intravenous to oral 
formulations, provided the same efficacy exists.  
The antibiotic recommendations for the treatment of CAP differ by guideline and are based on 
knowledge of local causative pathogens, antibiotic resistance patterns and patient illness severity. 
The Infectious Disease Society of America/American Thoracic Society guideline recommends that in 
the outpatient setting previously healthy individuals living in areas of low macrolide resistance 
should be treated with a macrolide (e.g. erythromycin, clarithromycin or azithromycin) or 
doxycycline, whilst those with co-morbidities, those in areas with high macrolide resistance or those 
admitted to hospital should receive a respiratory fluoroquinolone (moxifloxacin or levofloxacin) or a 
β-lactam (e.g. amoxicillin, amoxicillin-clavulanate or cefuroxime) plus a macrolide. For patients 
requiring admission to intensive care a β-lactam plus azithromycin or β-lactam plus a respiratory 
fluoroquinolone, with a respiratory fluoroquinolone plus aztreonam being recommended for 
penicillin allergic individuals. The British Thoracic Society recommends an oral β-lactam (amoxicillin 
is preferred) or doxycycline or clarithromycin for those with low illness severity (CURB-65=0–1), a β-
lactam (oral amoxicillin or intravenous benzylpenicillin) plus a macrolide (clarithromycin is preferred) 
or doxycycline or respiratory fluoroquinolone for those with moderate illness severity (CURB-65=2) 
and intravenous amoxicillin-clavulanate plus a macrolide or intravenous benzylpenicillin plus either 
levofloxacin or ciprofloxacin for those with high illness severity (CURB-65=3-5). Fluoroquinolone 
monotherapy is useful in the treatment of CAP(4, 5), however it is probably best reserved for those 
with low illness severity(6) or in those where L. pneumophila pneumonia is diagnosed. Furthermore, 
the combination of a fluoroquinolone with a β-lactam is advocated, but studies suggest that 
mortality is worse compared to when a β-lactam and macrolide combination is used(5–7). The 
empirical use of a macrolide together with a β-lactam antibiotic in CAP is justified by potentially 20% 
of CAP being caused by atypical pathogens (L. pneumophila, C. pneumoniae and M. pneumoniae)(3) 
and results in improved clinical outcomes even in the presence of drug resistant pathogens(6, 8–10).  
In the last decade, in certain geographical regions, due to the abundant use of antibiotics there has 
been an increase in antibiotic resistant respiratory pathogens. Of concern is the increase in penicillin 
and macrolide-resistant S. pneumoniae since this is the most commonly isolated pathogen. A recent 
study of 1713 S. pneumoniae isolates from four continents found that only 61.5% and 62.2% were 
sensitive to penicillin and azithromycin, respectively(11). The SENTRY antimicrobial surveillance 
program reported that in the United States the proportion of erythromycin-resistant S. pneumoniae 
in 2011 had increased to 55%(12). This figure is more alarming in Asia where 73% of S. pneumoniae 
isolates from a prospective surveillance study were erythromycin resistant(13). Although S. 
pneumoniae resistance to penicillin is increasing, β-lactam antibiotics at appropriate doses are still 
useful at treating infection(14, 15) and in countries such the UK and Netherlands that have a low 
proportion of penicillin- and erythromycin-resistant S. pneumoniae isolates the use of older 
generation antibiotics are recommended. However, macrolide-resistance is clinically important as 
there is evidence from a well conducted prospective study showing that macrolide-resistance is 
associated with treatment failure(16). However, treatment failure in this context does not appear to 
impact on mortality. This is confirmed by a more recent retrospective study that did not 
demonstrate any differences in outcome between hospitalised patients with or without macrolide-
resistant S. pneumoniae pneumonia, but it is important to note that <5% and <50% of patients 
received macrolide monotherapy or combination treatment with a β-lactam and macrolide(17). 
Nevertheless, with the changing epidemiology of respiratory pathogen resistance patterns there is 
great need to develop novel antibiotics to treat bacterial CAP.  
More recently solithromycin, a fourth generation antibacterial macrolide and first fluoroketolide, 
was developed. The novel chemistry, pharmacokinetics and pharmacodynamics of this drug are 
described in detail elsewhere(18, 19) and is beyond the scope of this article. Solithromycin is 
available as both an oral and intravenous preparation, is administered once daily and covers the 
same pathogens as other macrolides, but has the added advantage of being bactericidal rather than 
just bacteriostatic and is effective against bacteria which are resistant against current macrolides. In 
a study where 38% of S. pneumoniae isolates were resistant to azithromycin, 98.9% and 100% of 
isolates were inhibited by solithromycin at MIC values of ≤0.25 mg/L  and ≤1 mg/L, respectively(11). 
Solithromycin also inhibited 85.3% of methicillin-sensitive Staphylococcus aureus isolates of which 
only 58.7% were sensitive to azithromycin. Additionally, in healthy subjects solithromycin doesn’t 
significantly affect the QT interval(18, 20), which is a concern with macrolide use, such as 
azithromycin, and fluoroquinolones, such as moxifloxacin, and it does not appear to have the side 
effect profile that was seen with telithromycin, a third generation macrolide, which due to cases of 
drug-induced severe hepatic failure is no longer marketed(18). Another advantage is that 
solithromycin is more anti-inflammatory than currently used macrolides(21), which is beneficial, 
considering that immunomodulatory effects of macrolides is one of the suggested reasons for 
improved outcomes in severe CAP when combined with a β-lactam even in the absence of high 
proportions of atypical pathogens(6, 22, 23). The potential of this antibiotic to attenuate the levels 
of pro-inflammatory cytokines and excessive neutrophilic inflammation by inhibiting NFκB 
activity(21) may in the context of CAP lead to less lung injury as is observed with other potential 
immunomodulatory therapies (24, 25), however to date no clinical studies have been published 
looking at the efficacy of solithromycin in severe CAP, in reducing admissions for mechanical 
ventilation or adequately powered to detect differences in mortality. 
In a phase two randomised controlled, double-blind clinical study solithromycin was compared to 
levofloxacin in the treatment of adult CAP. All patients had to be suitable for oral therapy and most 
of the included patients were in PORT class II and 27% were ≥65 years of age. Solithromycin had 
comparable clinical success rates to levofloxacin (84.6% versus 86.6%) at four to eleven days post 
treatment(26). Furthermore, it had few treatment related adverse events (29.7% versus 45.6%)(26). 
This led to a phase three randomised, double-blind, multi-centre non-inferiority clinical trial 
comparing the efficacy of oral solithromycin to oral moxifloxacin in the treatment of CAP (SOLITAIRE-
ORAL)(27). In this study solithromcyin was administered for five days followed by two days of 
placebo whilst moxifloxacin was given for seven days, based on the duration of treatment with 
moxifloxacin in other CAP studies. Although this study included a greater proportion of patients 
classified as PORT class III, 96% of patients had a CURB-65 score ≤2, representing a population at low 
risk of death from CAP(27). Solithromycin had a similar early clinical response (defined as an 
improvement in at least two of four symptoms, including cough, chest pain, sputum production, and 
dyspnoea, with no worsening in any symptom at 72 h after the first dose) and treatment failure (lack 
of resolution, worsening of baseline symptoms or development of new symptoms, and need for new 
antibacterial treatment at 5-10 days post-treatment) to moxifloxacin in the treatment of CAP, 
suggesting that it will be a suitable alternative to highly bacteriocidal fluoroquinolones. However, it 
is important to note that the number of macrolide resistant S. pneumoniae isolates in this study 
were low. It is therefore difficult to know how solithromycin will perform in a clinical setting of high 
macrolide resistance, however based on the surveillance data highlighted above it is predicted that 
solithromycin would remain effective in this setting.  
Switching from intravenous antibiotics to less expensive oral formulations once the patient is 
clinically stable and suitable for oral therapy can reduce medication costs and potentially other 
associated costs by reducing length of hospitalisation and infusion-related adverse events.  Recently, 
in the journal Clinical Infectious Diseases, File et al.(28) published the results of the SOLITAIRE-IV 
study which compared the efficacy of intravenous to oral switching of solithromycin to that of 
moxifloxacin. Patients could be switched from intravenous to oral formulations for either treatment 
at the discretion of the clinician but in keeping with the following guidance: improvement of 
baseline clinical signs and symptoms; afebrile; respiratory rate ≤24 breaths per minute, systolic 
blood pressure ≥90 mmHg and oxygen saturation (as determined by pulse oximetry) ≥90% when 
breathing room air(28). Both the intravenous and oral dose of solithromycin and moxifloxacin was 
400 mg except for the first oral dose of solithromycin which was 800 mg. In this randomised 
controlled, double-blind multicentre study of 863 patients approximately 45% of patients were ≥65 
years of age. This represented the significant age group that develops CAP but only 7% had a CURB-
65 score ≥3, where the predicted mortality is >10%. This is reflected by the low mortality rate of 
1.2% and 1.6% in the solithromycin and moxifloxacin groups, respectively, and does not provide 
evidence for the efficacy of solithromycin in those at increased risk of death. An important aspect of 
this study was that although patients were recruited from 147 centre in 22 countries the 
microbiological assessments were done centrally in one laboratory leading to a high proportion of 
identified pathogens. S. pneumoniae was the most commonly identified pathogen but again <5% of 
S. pneumoniae isolates were macrolide-resistant. A high proportion (23%) of identified pathogens 
were atypical bacteria, mainly L. pneumophila and M. pneumoniae. Solithormycin was associated 
with more infusion site adverse events (31.3% versus 5.4%) resulting in discontinuation of treatment 
in 11 and 1 patients, respectively. This was not associated with the duration of intravenous 
treatment as this was similar between both groups. Overall, early discontinuation of treatment due 
to drug related adverse events was similar in both groups (5.8% and 4.2%). The clinical effectiveness 
determined by the early clinical response and short-term follow up visit was similar for both the 
solithormycin and moxifloxacin groups (79.3% versus 79.7% and 84.6% and 88.6%)(28), suggesting 
that switching oral to intravenous solithromycin was not inferior to moxifloxacin. 
Overall, available evidence supports the use of solithormycin in the treatment of adult CAP of mild to 
moderate severity. Although empiric use of once daily macrolide monotherapy with solithromycin 
appears an attractive option it is important to consider the non-financial cost of the widespread use 
of new macrolides, which will likely lead to the development of solithromycin-resistant bacterial 
isolates. This will ultimately result in the same problem that we currently encounter with older 
agents and therefore, it is likely that these new agents should be reserved for the treatment of CAP 
caused by microbiologically proven antibiotic-resistant bacteria without evidence of clinical 
improvement where current guideline recommended regimens are failing.  
Despite current data indicating that solithromycin is non-inferior to fluoroqinolones in the treatment 
of CAP, the US Food and Drug Adminsitration (FDA) has not approved the use of solithromycin(29). It 
has acknowledged the efficacy of solithromycin for the treatment of bacterial CAP but a major 
concern to the licensing of solithromycin is the potential risk of severe idiosyncratic drug induced 
liver injury and has recommended that the manufacturer should conduct a clinical safety study that 
exposes 9000 individuals to solithromycin. Such a study will be expensive and time-consuming, and 
it is therefore unknown if this next step will be undertaken by the manufacturer. The development 
of novel antibiotics for the treatment of CAP is an unmet need and once reassurances are provided 
regarding severe hepatotoxicity we may see the rise of solithromycin.  
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